Compare DraftKings Inc (DKNG) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DraftKings Inc vs BIO-TECHNE Corp — how do they compare? DraftKings Inc trades at $19.9 (market cap $9.51B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while DraftKings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold DraftKings Inc for 55 Days and BIO-TECHNE Corp for 63 Days on average.
| DKNG | TECH | |
|---|---|---|
Market Cap | $9.51B | $11.37B |
Volume | 11,829,779 | 3,153,511 |
Sector | Consumer Cyclical | Health |
52-Week High | $36.24 | $72.61 |
52-Week Low | $18.59 | $43.31 |
Typical Hold Time | 55 Days | 63 Days |
Enterprise Value | $10.44B | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DraftKings (DKNG) trades at $19.87, near its 52-week low, with a bearish technical outlook despite strong analyst support. The company achieved profitability in 2025 with $6.05B revenue and positive net income of $3.71M, though recent quarters show earnings misses. Operating cash flow improved to $663M in 2025, but high valuation multiples (P/E 246.33) and negative ROE (-22.12%) highlight risks. Recent news focuses on prediction market expansion and NFL season performance.
The stock faces near-term pressure from technical weakness and earnings volatility, but long-term growth drivers in sports betting and predictions remain intact. Wall Street maintains strong bullish sentiment with a $33.13 price target, though investors should weigh high valuation against execution risks and competitive threats in the evolving gaming landscape.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
